Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Contact Supplier

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

DIGITAL CONTENT

4 NEWS #PharmaBuzz

media
4 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

7DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Lorecivivint, 1467093-03-3, Sm04690, Lorecivivint [usan], N-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide, Adavivint (sm04690)

Molecular Formula

C₂₉H₂₄FN₇O

Molecular Weight

505.5 g/mol

InChI Key

AQDWDWAYVBQMAM-UHFFFAOYSA-N

FDA UNII

42EK42WHI5

Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease).

1 2D Structure

Lorecivivint

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[5-[3-[7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-5-yl]pyridin-3-yl]-3-methylbutanamide

2.1.2 InChI

InChI=1S/C29H24FN7O/c1-16(2)8-26(38)33-21-10-19(12-31-13-21)17-6-7-24-22(11-17)28(37-36-24)29-34-25-15-32-14-23(27(25)35-29)18-4-3-5-20(30)9-18/h3-7,9-16H,8H2,1-2H3,(H,33,38)(H,34,35)(H,36,37)

2.1.3 InChI Key

AQDWDWAYVBQMAM-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)CC(=O)NC1=CN=CC(=C1)C2=CC3=C(C=C2)NN=C3C4=NC5=C(N4)C=NC=C5C6=CC(=CC=C6)F

2.2 Other Identifiers

2.2.1 UNII

42EK42WHI5

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Lorecivivint

2. N-(5-((3z)-3-(7-(3-fluorophenyl)imidazo(4,5-c)pyridin-2-ylidene)-1,2-dihydroindazol-5-yl)pyridin-3-yl)-3-methylbutanamide

3. Sm-04690

4. Sm04690

2.3.2 Depositor-Supplied Synonyms

1. Lorecivivint

2. 1467093-03-3

3. Sm04690

4. Lorecivivint [usan]

5. N-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide

6. Adavivint (sm04690)

7. Sm-04690

8. 42ek42whi5

9. 1467093-03-3 (free Base)

10. N-(5-(3-(7-(3-fluorophenyl)-3h-imidazo(4,5-c)pyridin-2-yl)-1h-indazol-5- Yl)-pyridin-3-yl)-3-methylbutanamide

11. Adavivint [inn]

12. N-[5-[3-[7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl]-1h-indazol-5-yl]pyridin-3-yl]-3-methylbutanamide

13. Adavivint; Sm04690

14. Lorecivivint (usan/inn)

15. Lorecivivint [inn]

16. Adavivint (deprecated Inn)

17. Unii-42ek42whi5

18. Gtpl9620

19. Chembl4297639

20. Schembl15302155

21. Bcp30409

22. Ex-a2711

23. Mfcd30489411

24. S8761

25. Who 10389

26. Db14883

27. Ac-31570

28. As-84223

29. Sm0-4690

30. Hy-109049

31. Cs-0031495

32. D11588

33. D83694

34. A934079

35. Sm04690; Sm-04690; Sm 04690 Pound>>cas:1467013-03-3

36. Butanamide, N-(5-(3-(7-(3-fluorophenyl)-3h-imidazo(4,5-c)pyridin-2-yl)-1h- Indazol-5-yl)-3-pyridinyl)-3-methyl-

37. N-(5-((3z)-3-(7-(3-fluorophenyl)imidazo(4,5-c)pyridin-2-ylidene)-1,2-dihydroindazol-5-yl)pyridin-3-yl)-3-methylbutanamide

38. N-(5-{3-[7-(3-fluorophenyl)-1h-imidazo[4,5-c]pyridin-2-yl]-1h-indazol-5-yl}pyridin-3-yl)-3-methylbutanamide

2.4 Create Date

2019-01-15

3 Chemical and Physical Properties

Molecular Formula	C₂₉H₂₄FN₇O
Molecular Weight	505.5 g/mol
XLogP3	4.5
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	6
Exact Mass	505.20263658 g/mol
Monoisotopic Mass	505.20263658 g/mol
Topological Polar Surface Area	112 Å²
Heavy Atom Count	38
Formal Charge	0
Complexity	816
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Anti-Inflammatory Agents

Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Lorecivivint manufacturers, exporters & distributors on PharmaCompass

Lorecivivint

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

7 Drugs in Development

DIGITAL CONTENT

4 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

7DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?